{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"10"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"10"}],"units":"Participants"}],"description":"The severity of TEAEs were graded using the CTCAE version 5.0 with the exception of CRS and TLS, which graded using the criteria referenced in the publication by Lee et al, 2014 and the Cairo Bishop criteria referenced in the publication by Coiffier et al, 2008. Any clinically significant changes in vital signs, electrocardiograms (ECGs) and clinical laboratory tests were recorded as TEAEs.","groups":[{"description":"28 day continuous intravenous infusion of AMG 420 200 µg/day followed by a 2 week treatment-free interval, until progressive disease (PD) or relapse as defined by International Myeloma Working Group (IMWG) response criteria, unacceptable safety events, next anti-multiple myeloma treatment, or other reason for permanent treatment discontinuation","id":"OG000","title":"AMG 420 200 µg/Day"},{"description":"28 day continuous intravenous infusion of AMG 420 400 µg/day followed by a 2 week treatment-free interval, until PD or relapse as defined by IMWG response criteria, unacceptable safety events, next anti-multiple myeloma treatment, or other reason for permanent treatment discontinuation","id":"OG001","title":"AMG 420 400 µg/Day"},{"description":"28 day continuous intravenous infusion of AMG 420 600 µg/day followed by a 2 week treatment-free interval, until PD or relapse as defined by IMWG response criteria, unacceptable safety events, next anti-multiple myeloma treatment, or other reason for permanent treatment discontinuation","id":"OG002","title":"AMG 420 600 µg/Day"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety analysis set defined as all participants that are enrolled and receive at least 1 dose of AMG 420.","reportingStatus":"POSTED","timeFrame":"Up to approximately 3 years","title":"Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE)","type":"PRIMARY","unitOfMeasure":"Participants"}